To date, only one prospective clinical trial was carried out applying [177Lu]Lu-PSMA in low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients and revealed it to be a feasible and safe treatment modality [27]. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.